Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol
Clinical Chemistry · 04.11.2025 · 71 (11) · 1138-1146
DOI: 10.1093/clinchem/hvaf099 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Chemistry, online erschienen am 03.09.2025. Verfasst von Jeffrey W Meeusen und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States. Hauptthemen laut MEDLINE: Hypertriglyceridemia, Cholesterol, LDL. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Intramural Research Program of the National Heart, Lung, and Blood Institute, NIH HHS, Leducq Foundation for Cardiovascular Research.
Abstract (Originalsprache)
Background
Direct measurement of low-density lipoprotein cholesterol (LDL-C) is widely used and recommended by professional society guidelines despite its potential limitations in patients with hypertriglyceridemia and low LDL-C. This study evaluated the performance of 3 direct LDL-C (LDL-CD) assays, 2 modern LDL-C calculation methods [LDL-C Martin (LDL-CM), LDL-C modified Sampson (LDL-CS)] and the conventional Friedewald (LDL-CF) method against the reference method, beta-quantification (LDL-CBQ).
Methods
A total of 181 remnant sera from patients with standard lipid panel orders or from patients with LDL-CBQ orders with triglycerides (TG) ≥ 400 mg/dL (4.5 mmol/L), or with TG ≥ 150 mg/dL (1.69 mmol/L) and LDL-C < 70 mg/dL (1.8 mmol/L) were included. LDL-CD and lipid panel data were gathered from Abbott Alinity, Roche Cobas, and Siemens Atellica platforms.
Results
LDL-CD among the 3 platforms showed a median CV of 11.2%. In patients with TG <400 mg/dL, LDL-CM and LDL-CS demonstrated less bias and less misclassification at the clinical decision LDL-C levels than LDL-CF or LDL-CD. In the 400 to 800 mg/dL (9.0 mmol/L) TG group, LDL-CS was superior to LDL-CD or LDL-CM in accuracy. When TG is ≥ 800 mg/dL, LDL-CD (Roche) showed substantial bias from LDL-CBQ while LDL-CS (Roche) showed smaller but significant bias.
Conclusions
In summary, LDL-CD or LDL-CF showed little advantage over the 2 modern LDL-C calculation methods. LDL-CS showed the best overall correlation with LDL-CBQ and therefore is recommended to replace LDL-CF and potentially LDL-CD when making clinical decisions in patients with low LDL-C and hypertriglyceridemia.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, United States.
- Department of Clinical Pathology and Genomic Medicine, Houston Methodist Hospital, Houston, TX, United States.
- Department of Pathology and Laboratory Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, United States.
- Department of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States.
- Children's Health, Dallas, TX, United States.
- Lipoprotein Metabolism Laboratory, Translational Vascular Medicine Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, United States.
ORCID-Profile: Xin Yi, Leslie J Donato, Patricia M Jones, Rafael Zubirán, Jing Cao
Förderung
- Intramural Research Program of the National Heart, Lung, and Blood Institute
- NIH HHS
- Leducq Foundation for Cardiovascular Research
- Department of Pathology at the University of Texas Southwestern Medical Center
- National Institutes of Health
Zitieren
APA
Meeusen, J. W., Yi, X., Cotten, S. W., Nielsen, J. B., Donato, L. J., Jones, P. M., Muthukumar, A. R., Zubirán, R., Remaley, A. T., & Cao, J. (2025). Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol. Clinical Chemistry, 71(11), 1138-1146. https://doi.org/10.1093/clinchem/hvaf099
Vancouver
Meeusen JW, Yi X, Cotten SW, Nielsen JB, Donato LJ, Jones PM, et al. Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol. Clinical Chemistry. 2025;71(11):1138-1146. doi:10.1093/clinchem/hvaf099
BibTeX
@article{Meeusen2025,
author = {Meeusen, Jeffrey W and Yi, Xin and Cotten, Steven W and Nielsen, Jacob B and Donato, Leslie J and Jones, Patricia M and Muthukumar, Alagar R and Zubirán, Rafael and Remaley, Alan T and Cao, Jing},
title = {Modern Low-Density Lipoprotein Cholesterol Formulas Outperform Direct Methods in Patients with Hypertriglyceridemia and Low Levels of Low-Density Lipoprotein Cholesterol},
journal = {Clinical Chemistry},
year = {2025},
volume = {71},
number = {11},
pages = {1138--1146},
doi = {10.1093/clinchem/hvaf099}
}
EUVIMED